Intarcia Therapeutics IPO

Intarcia is a biotech company dedicated to redesigning the treatment, prevention and experience of chronic disease.

Register for Details

For more details on financing and valuation of private companies similar to Intarcia Therapeutics before its CO, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Intarcia Therapeutics

To invest in Intarcia Therapeutics pre-IPO

Can you invest in Intarcia Therapeutics pre-IPO?

You can no longer invest in Intarcia Therapeutics. But if you are an accredited investor interested in buying pre-IPO shares of a private company, you can learn more about how to invest in the private market or register today to get started.

Can you sell shares of Intarcia Therapeutics before it goes public?

You can no longer sell shares of Intarcia Therapeutics on Forge as this company ceased its operations. However, if you own shares of a private company, Forge may be able to help you sell them in a way that works for you and the company. Learn more or register with us today to get started.

What is the pre-IPO value of my Intarcia Therapeutics shares?

Forge can no longer determine the value of Intarcia Therapeutics shares as this company is no longer private. However, if you own shares of a private company, Forge may help you value and sell them in a way that works for you and the company. Learn more or register with us today to get started.

Is Intarcia Therapeutics a publicly traded company?

Intarcia Therapeutics ceased its operations.

To learn more about Intarcia Therapeutics potential IPO

Will Intarcia Therapeutics go IPO?

Intarcia Therapeutics ceased its operations.

What is Intarcia Therapeutics’ IPO price?

Intarcia Therapeutics has ceased operations and never went public, so there is no IPO price available.

When was Intarcia Therapeutics founded?

Intarcia Therapeutics was founded in 1995.

What is Intarcia Therapeutics funding to date?

Intarcia Therapeutics has raised $961.46MM to date.

Who are Intarcia Therapeutics’s major investors?

New Enterprise Associates
GGV Capital
Venrock
Foresite Capital
Farallon Capital Management
Fred Alger Management
New Leaf Venture Partners
Quilvest
RA Capital

Intarcia Therapeutics Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
09/15/2016 Series EE $475.68MM $xx.xx $3.94B Baillie Gifford, Luxin Venture Capital, Fidelity Investments, RA Capital Management, Foresite Capital Management, The Pritzker Organization, The Baupost Group
Price per Share
$xx.xx
Shares Outstanding
14,166,667
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Baillie Gifford, Luxin Venture Capital, Fidelity Investments, RA Capital Management, Foresite Capital Management, The Pritzker Organization, The Baupost Group
07/04/2014 Series DD $200MM $xx.xx $1.63B RA Capital, Fallon Capital Management, Foresite Capital, Franklin Templeton, Fred Alger Management, New Leaf Venture Partners, Quilvest, Adams Street Partners, Fidelity Investments
Price per Share
$xx.xx
Shares Outstanding
6,174,746
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
RA Capital, Fallon Capital Management, Foresite Capital, Franklin Templeton, Fred Alger Management, New Leaf Venture Partners, Quilvest, Adams Street Partners, Fidelity Investments
11/15/2012 Series CC $210MM $xx.xx $612MM Venrock, New Leaf Venture Partners, New Enterprise Associates, Foresite Capital Management, Marker, The Baupost Group, Farallon Capital Management, Fidelity Investments
Price per Share
$xx.xx
Shares Outstanding
12,199,570
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Venrock, New Leaf Venture Partners, New Enterprise Associates, Foresite Capital Management, Marker, The Baupost Group, Farallon Capital Management, Fidelity Investments
01/14/2010 Series BB-3 $7.87MM $xx.xx $138MM New Leaf Venture Partners, Venrock Associates, New Enterprise Associates
Price per Share
$xx.xx
Shares Outstanding
1,119,341
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
New Leaf Venture Partners, Venrock Associates, New Enterprise Associates
04/28/2008 Series BB-2 $24.99MM $xx.xx $112MM New Leaf Venture Partners, Quilvest Ventures, New Enterprise Associates, Venrock Associates, Alta Partners, Omega Fund, Bay City Ventures, Granite Global Ventures
Price per Share
$xx.xx
Shares Outstanding
3,786,364
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
New Leaf Venture Partners, Quilvest Ventures, New Enterprise Associates, Venrock Associates, Alta Partners, Omega Fund, Bay City Ventures, Granite Global Ventures
03/09/2007 Series BB-1 $23.84MM $xx.xx $103.02MM New Leaf Venture Partners, Quilvest Ventures, New Enterprise Associates, Venrock Associates, Alta Partners, Omega Fund, Bay City Ventures, Granite Global Ventures
Price per Share
$xx.xx
Shares Outstanding
3,974,119
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
New Leaf Venture Partners, Quilvest Ventures, New Enterprise Associates, Venrock Associates, Alta Partners, Omega Fund, Bay City Ventures, Granite Global Ventures
12/01/2004 Series AA $19.08MM $xx.xx $98MM Undisclosed investors
Price per Share
$xx.xx
Shares Outstanding
3,180,135
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
Undisclosed investors
Updated on: Nov 21, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.